June 22, 2012

Sanofi Pasteur’s 6-in-1 Pediatric Vaccine Hexaxim™ Receives Positive Opinion from European Medicines Agency

- EMA scientific opinion opens the door for registration of Hexaxim™ in international markets outside Europe -
- HexaximTM, the only fully-liquid, ready to use 6-in-1 pediatric vaccine to improve the standard of care of childhood vaccination worldwide -

 

Sanofi Pasteur’s 6-in-1 Pediatric Vaccine Hexaxim™ Receives Positive Opinion from European Medicines Agency
- EMA scientific opinion opens the door for registration of Hexaxim™ in international markets outside Europe -
- HexaximTM, the only fully-liquid, ready to use 6-in-1 pediatric vaccine to improve the standard of care of childhood vaccination worldwide -

France, Lyon – June 22, 2012 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that HexaximTM (DTaP-IPV-Hib-HepB vaccine) received a positive scientific opinion from the European Medicines Agency (EMA), as part of a procedure designed to evaluate medicinal products intended for markets outside the European Union. This is the first time the EMA gives a positive scientific opinion to a vaccine following that procedure. Hexaxim™ is the only fully liquid, ready to use 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.